Protease-Cleavable Prodrug for Targeted Antimicrobial Peptide Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial peptides (AMPs) face challenges with off-target toxicity and low stability in vivo, and there is a need for effective treatments against multidrug-resistant bacteria, particularly those that exhibit tolerance or persistence strategies, as well as defiant bacterial populations that proliferate in the presence of active prodrugs.
Innovation Solution
Development of bacterial protease-activated prodrug compositions, where a cationic antimicrobial peptide is conjugated to an anionic peptide via a protease-cleavable linker, remaining inactive until cleaved by bacterial proteases, allowing for targeted activation and auto-titration, along with mathematical modeling to determine the Bacterial Advantage Heuristic (BAH) for effective treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antimicrobial peptides are used to treat bacterial infection, then bacterial killing effectiveness is improved, but off-target toxicity increases
Solution Approach 1:
The patent uses bacterial proteases as intermediaries to activate the prodrug form of antimicrobial peptides. The prodrug is designed with a protease-cleavable linker that is specifically recognized and cleaved by bacterial proteases, releasing the active antimicrobial peptide only at the infection site. This intermediary activation mechanism ensures that the toxic AMPs are not present in their active form in healthy tissues, thereby reducing off-target toxicity while maintaining effective bacterial killing where the protease is present.
Solution Approach 2:
The patent changes the chemical state of the antimicrobial peptide from active to inactive by conjugating it to a prodrug moiety via a protease-cleavable linker. This parameter change (from active AMP to prodrug conjugate) reduces the toxicity of the compound in circulation. Upon bacterial protease cleavage, the parameter changes back to the active state, restoring full antimicrobial activity. This dynamic parameter change allows the same compound to have different properties in different physiological contexts.
2Productivity
If antimicrobial peptides are administered to kill bacteria, then bacterial population reduction is improved, but stability in vivo deteriorates
Solution Approach 1:
The prodrug conjugate acts as an intermediary that protects the antimicrobial peptide from degradation in vivo. The peptide is shielded within the conjugate structure, which prevents premature degradation by host proteases and other biological factors. The bacterial protease serves as the specific mediator that triggers release of the protected peptide only when needed, thereby maintaining both stability during circulation and activity at the target site.
Solution Approach 2:
The patent performs preliminary protection of the antimicrobial peptide by conjugating it to the prodrug carrier before administration. This preliminary action (conjugation) stabilizes the peptide against degradation during storage and circulation. The stabilization is temporary and reversible, as the bacterial protease subsequently cleaves the linker to release the active peptide when it encounters the bacterial infection, thus achieving both stability and bioavailability.
3Object-affected harmful factors
If prodrugs are used to reduce off-target toxicity, then off-target effects are reduced, but activation mechanism complexity increases
Solution Approach 1:
The prodrug system is designed to be self-activating through the bacterial protease that is naturally present at the infection site. The bacterial protease serves the dual function of both being a marker of bacterial presence and the enzyme that activates the prodrug. This self-service mechanism eliminates the need for external activation systems, complex delivery devices, or additional activation enzymes, thereby reducing overall system complexity while maintaining targeted activation and reduced off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The prodrug compositions effectively kill bacteria with reduced off-target toxicity and improved stability, while the BAH metric helps in predicting and overcoming bacterial defiance, ensuring effective treatment across various environmental and genetic conditions.
Implementation Method 1
The protease-cleavable linker substrate can be a protease substrate for a bacterial protease... cleavage of the protease-cleavable linker substrate releases the cationic antimicrobial peptide from the anionic peptide
Data Source
AI summary
Disclosed herein are bacterial protease-activated prodrug compositions and methods of their use for the treatment and prevention of bacterial infection. Also disclosed are methods of reducing or eliminating defiant bacterial populations. An exemplary prodrug composition includes a cationic antimicrobial peptide conjugated to an anionic peptide with a protease-cleavable linker substrate, wherein the antimicrobial peptide is inactive while it is in conjugation with the anionic peptide. Upon cleavage by the protease, the cationic AMP is released from the anionic peptide and can act upon bacteria. The protease is specific to the bacteria that are present in the sample or the subject, creating an auto-titrating mechanism wherein the AMP is released from the peptide only when there is bacteria present.